Hosted on MSN1mon
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis PigmentosaWithout intervention, many patients with RP face the risk of legal blindness ... treated eyes achieved a statistically significant two-line gain (10 letters) in low-luminance visual acuity ...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results